Results 181 to 190 of about 8,113 (209)
Some of the next articles are maybe not open access.
Bosentan in systemic sclerosis
Drugs of Today, 2008Systemic sclerosis (SSc) is a relatively rare chronic connective tissue disease characterized by varying degrees of skin fibrosis and visceral organ involvement. Pulmonary compromise, including pulmonary arterial hypertension and interstitial lung disease, is currently the leading cause of death in patients with SSc.
Omar A. Minai, Gustavo A. Heresi
openaire +3 more sources
Heart Disease, 2003
Bosentan is the first endothelin (ET) receptor antagonist approved by the Food and Drug Administration for the management of pulmonary arterial hypertension (PAH). In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance.
openaire +2 more sources
Bosentan is the first endothelin (ET) receptor antagonist approved by the Food and Drug Administration for the management of pulmonary arterial hypertension (PAH). In patients with World Health Organization Class III and IV PAH, bosentan has demonstrated improvement in dyspnea and exercise tolerance.
openaire +2 more sources
Hospital Pharmacy, 2008
Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses.
Dennis J. Cada, Joyce A. Generali
openaire +2 more sources
Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses.
Dennis J. Cada, Joyce A. Generali
openaire +2 more sources
Bosentan for the treatment of scleroderma
Future Rheumatology, 2006Bosentan is the first orally active, high-affinity endothelin dual receptor antagonist approved for the treatment of pulmonary arterial hypertension. Elevated circulating levels and increased tissue expression of endothelin-1 are characteristic of scleroderma and patients demonstrate endothelin receptor overexpression in affected tissues and organs ...
David Launay +2 more
openaire +2 more sources
Bosentan Therapy for Pulmonary Arterial Hypertension
New England Journal of Medicine, 2002Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension.
Rubin, Lewis J. +11 more
openaire +3 more sources
Bosentan: a dual endothelin receptor antagonist
Expert Opinion on Investigational Drugs, 2002The peptide endothelin plays a significant role in a wide array of pathological conditions, including primary pulmonary hypertension and pulmonary arterial hypertension associated with collagen vascular disease. These are life-threatening conditions that can severely compromise the function of the lungs and heart.
Sébastien Roux, Lewis J. Rubin
openaire +2 more sources
Bosentan therapy for pulmonary arterial hypertension
American Journal of Health-System Pharmacy, 2004The etiology, epidemiology, pathophysiology, diagnosis, and manifestations of pulmonary arterial hypertension (PAH) are described, and the role of bosentan in the management of PAH is reviewed.The incidence of primary pulmonary hypertension, a subcategory of PAH, is estimated to be one to two new cases per million people annually in the general ...
Alan Hui +3 more
openaire +3 more sources
Bosentan for the Treatment of Adult Pulmonary Hypertension
Future Cardiology, 2010Pulmonary hypertension is a severe progressive disease with a marked morbidity and a high mortality attributed to right heart failure. Bosentan, a dual endothelin receptor antagonist, is an effective and well-tolerated oral therapy for the management of pulmonary arterial hypertension (PAH; WHO group 1 pulmonary hypertension).
Nathan Dwyer +2 more
openaire +3 more sources
Bosentan et fibrose pulmonaire
La Revue de Médecine Interne, 2007Resume La fibrose pulmonaire idiopathique (FPI) caracterisee par un aspect histopathologique de pneumopathie interstitielle commune est la plus frequente et la plus grave des PID idiopathiques. Aucun traitement n'a montre a ce jour une amelioration de la survie au cours de la FPI.
Vincent Cottin, J.F. Cordier
openaire +2 more sources
▼Bosentan for pulmonary arterial hypertension
Drug and Therapeutics Bulletin, 2003Pulmonary arterial hypertension is an uncommon but disabling and often fatal condition, in which there is a sustained rise in pulmonary arterial pressure due to progressive obliteration of the pulmonary vascular bed. ▼Bosentan (Tracleer - Actelion), which belongs to a new class of drugs called endothelin receptor antagonists, is now available for ...
openaire +2 more sources